Back

MNRR1 activation by nitazoxanide abrogates lipopolysaccharide- induced preterm birth in mice

Purandare, N.; Gomez-Lopez, N.; Arenas-Hernandez, M.; Galaz, J.; Romero, R.; Xi, Y.; Fribley, A.; Grossman, L. I.; Aras, S.

2023-02-01 immunology
10.1101/2023.01.30.525762 bioRxiv
Show abstract

Intra-amniotic inflammation leading to preterm birth is one of the leading causes of neonatal morbidity and mortality. We recently found that the mitochondrial levels of MNRR1 (Mitochondrial Nuclear Retrograde, Regulator 1; also called CHCHD2, AAG10, or PARK22), an important bi-organellar regulator of cellular function, are reduced in the context of inflammation and that both genetic and pharmacological increase in MNRR1 levels can counter the inflammatory profile. We show here that nitazoxanide, a clinically-approved drug, is an activator of MNRR1 and prevents preterm birth in a well-characterized murine model caused by intra-amniotic lipopolysaccharide (LPS) injection. HighlightsO_LINitazoxanide exerts anti-inflammatory functions via activation of MNRR1. C_LIO_LIOral administration of nitazoxanide prevents preterm birth in mouse model of intra-intraamniotic LPS-induced inflammation. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.